Natpar (parathyroid hormone): Discontinuation of manufacturing at the end of 2024 and update on 100mcg shortage.

Summary:

• Manufacturing of all strengths of Natpar will be discontinued globally at the end of 2024, due to unresolved manufacturing challenges. This means that Natpar will be withdrawn from the global market. 
• Beyond 2024, Takeda intends to supply available doses until inventory is depleted or expired. Takeda will provide updates before the manufacturing end date and ahead of any further potential supply interruptions.
• A shortage of the 100 mcg/dose strength will continue until the discontinuation of manufacturing. Healthcare professionals can prescribe an alternative dosing regimen of Natpar, as per their clinical judgment (see details below).
• When changing the dosing or discontinuing Natpar, it is essential to closely monitor serum calcium levels and to monitor patients for signs and symptoms of hypocalcemia, while carefully adjusting active vitamin D and supplemental calcium doses in all patients.
• Healthcare professionals are advised not to initiate any new patients on any strength of Natpar.